Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.32 |
| ▸ | FEN1 | P39748 | 3/20 | 0.32 |
| ▸ | MET | P08581 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30867968 | 1.00 | NOS3 (0.34) | NOS3NOS1NOS2P2RX3P2RX2 | |
| SCHEMBL30868421 | 0.81 | DEGS1 (0.31) | NOS3NOS1NOS2VRK1CPB2 | |
| SCHEMBL30868338 | 0.81 | USP2 (0.39) | NOS3NOS1NOS2VRK1CPB2 | |
| SCHEMBL30144075 | 0.78 | EIF4A3 (0.33) | EIF4A3 | |
| SCHEMBL8030847 | 0.78 | EIF4A3 (0.33) | EIF4A3 | |
| SCHEMBL15471948 | 0.78 | HTT (0.42) | NOS3NOS1NOS2P2RX3P2RX2 | |
| SCHEMBL14225108 | 0.77 | S1PR1 (0.33) | EIF4A3 | |
| SCHEMBL22076927 | 0.77 | GABRA1 (0.38) | VRK1HTTALDH1A1GAAALOX12 | |
| SCHEMBL29910000 | 0.77 | GABRA1 (0.38) | NOS3NOS1NOS2P2RX3P2RX2 | |
| SCHEMBL84407 | 0.77 | NOS3 (0.56) | NOS3NOS1NOS2P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024028169-A1 | NOVEL SPECIFICALLY SUBSTITUTED THIOPHENOLIC COMPOUNDS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-02-08 | — | — | WO | disclosed |
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230060011-A1 | ANTIBACTERIAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2023-02-23 | — | — | US | disclosed |
| WO-2021250399-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2021-12-16 | — | — | WO | disclosed |
| US-20210032207-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
| US-20170369510-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170362180-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2017-12-21 | — | — | US | disclosed |
| US-8987268-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| WO-2012040137-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362180-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | NOS3 2932/4885NOS1 2578/4885NOS2 3360/4885 |
| US-20230060011-A1 | ANTIBACTERIAL COMPOUNDS | GAA, MGAM, NQO1 | NOS3 2108/4885NOS1 879/4885NOS2 1261/4885 |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | NOS3 105/4885NOS1 618/4885NOS2 614/4885 |
| US-20170369510-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | NLK, DCLK2, DLK1 | NOS3 2827/4885NOS1 2967/4885NOS2 2895/4885 |
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | ATR, CHEK1, CHEK2 | NOS3 3840/4885NOS1 3778/4885NOS2 3967/4885 |
| US-20210032207-A1 | QUINOLONE COMPOUND | HAX1, NQO2, CXCR1 | NOS3 3025/4885NOS1 2613/4885NOS2 3393/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | NOS3 4589/4885NOS1 4742/4885NOS2 4753/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | NOS3 4072/4885NOS1 4196/4885NOS2 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.